

Martino Introna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/581977/publications.pdf>

Version: 2024-02-01

224
papers

15,122
citations

14644

66
h-index

20943

115
g-index

228
all docs

228
docs citations

228
times ranked

14643
citing authors

#	ARTICLE	IF	CITATIONS
1	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. <i>Blood</i> , 2000, 95, 3900-3908.	0.6	523
2	Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo. <i>Journal of Immunology</i> , 2003, 171, 1581-1587.	0.4	519
3	CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. <i>Blood</i> , 2001, 98, 3383-3389.	0.6	395
4	PTX3, A Prototypical Long Pentraxin, Is an Early Indicator of Acute Myocardial Infarction in Humans. <i>Circulation</i> , 2000, 102, 636-641.	1.6	384
5	Cytokine regulation of endothelial cell function: from molecular level to the bedside. <i>Trends in Immunology</i> , 1997, 18, 231-240.	7.5	370
6	Multimer Formation and Ligand Recognition by the Long Pentraxin PTX3. <i>Journal of Biological Chemistry</i> , 1997, 272, 32817-32823.	1.6	353
7	Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice. <i>Stem Cells</i> , 2008, 26, 2075-2082.	1.4	351
8	Cross-Linking of the Mannose Receptor on Monocyte-Derived Dendritic Cells Activates an Anti-Inflammatory Immunosuppressive Program. <i>Journal of Immunology</i> , 2003, 171, 4552-4560.	0.4	334
9	Transfer of Growth Factor Receptor mRNA Via Exosomes Unravels the Regenerative Effect of Mesenchymal Stem Cells. <i>Stem Cells and Development</i> , 2013, 22, 772-780.	1.1	300
10	The Cytolytically Inactive Terminal Complement Complex Activates Endothelial Cells to Express Adhesion Molecules and Tissue Factor Procoagulant Activity. <i>Journal of Experimental Medicine</i> , 1997, 185, 1619-1628.	4.2	289
11	Autologous Mesenchymal Stromal Cells and Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 412-422.	2.2	273
12	Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. <i>Blood</i> , 1994, 84, 3483-3493.	0.6	244
13	Functional Properties of Human Vascular Endothelial Cadherin (7B4/Cadherin-5), an Endothelium-Specific Cadherin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 1229-1239.	1.1	231
14	M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro. <i>Journal of Immunology</i> , 2009, 182, 4415-4422.	0.4	227
15	Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. <i>Blood</i> , 2013, 122, 3482-3491.	0.6	206
16	Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. <i>Blood</i> , 1996, 87, 1862-1872.	0.6	201
17	Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab. <i>Journal of Immunology</i> , 2011, 186, 3762-3769.	0.4	198
18	Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. <i>Blood</i> , 2011, 118, 3301-3310.	0.6	188

#	ARTICLE	IF	CITATIONS
19	Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 375-381.	2.0	181
20	Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. <i>British Journal of Haematology</i> , 2001, 114, 800-809.	1.2	175
21	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. <i>Blood</i> , 2000, 95, 3900-8.	0.6	173
22	Safety of retroviral gene marking with a truncated NGF receptor. <i>Nature Medicine</i> , 2003, 9, 367-369.	15.2	169
23	Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). <i>Clinical and Experimental Immunology</i> , 2000, 119, 196-202.	1.1	168
24	Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. <i>Haematologica</i> , 2007, 92, 952-959.	1.7	165
25	Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1293-1301.	2.0	165
26	Mechanism of action of rituximab. <i>Anti-Cancer Drugs</i> , 2002, 13, S3-S10.	0.7	161
27	Life-Sparing Effect of Human Cord Blood-Mesenchymal Stem Cells in Experimental Acute Kidney Injury. <i>Stem Cells</i> , 2010, 28, 513-522.	1.4	161
28	Mutations in v-myb alter the differentiation of myelomonocytic cells transformed by the oncogene. <i>Cell</i> , 1990, 63, 1287-1297.	13.5	159
29	Localization of Mesenchymal Stromal Cells Dictates Their Immune or Proinflammatory Effects in Kidney Transplantation. <i>American Journal of Transplantation</i> , 2012, 12, 2373-2383.	2.6	151
30	Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. <i>Bone Marrow Transplantation</i> , 2007, 40, 785-791.	1.3	148
31	Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. <i>Transplant International</i> , 2013, 26, 867-878.	0.8	148
32	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. <i>Haematologica</i> , 2015, 100, 77-86.	1.7	147
33	Characterization of the Promoter for the Human Long Pentraxin PTX3. <i>Journal of Biological Chemistry</i> , 1997, 272, 8172-8178.	1.6	144
34	The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F. <i>Leukemia</i> , 2008, 22, 740-747.	3.3	141
35	Genetic Modification of Human T Cells with CD20: A Strategy to Purify and Lyse Transduced Cells with Anti-CD20 Antibodies. <i>Human Gene Therapy</i> , 2000, 11, 611-620.	1.4	126
36	Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. <i>Nature Communications</i> , 2017, 8, 983.	5.8	124

#	ARTICLE	IF	CITATIONS
37	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. <i>Blood</i> , 2000, 95, 3900-3908.	0.6	124
38	Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. <i>Experimental Hematology</i> , 2009, 37, 616-628.e2.	0.2	121
39	Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist.. <i>Journal of Experimental Medicine</i> , 1995, 182, 623-628.	4.2	112
40	Expression of c-myb and B-myb, but not A-myb, correlates with proliferation in human hematopoietic cells. <i>Blood</i> , 1991, 77, 149-158.	0.6	110
41	Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. <i>Cytotherapy</i> , 2011, 13, 786-801.	0.3	104
42	Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired immunodeficiency syndrome: selective impairment of chemotaxis. <i>Clinical and Experimental Immunology</i> , 1985, 62, 136-42.	1.1	103
43	The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. <i>Leukemia</i> , 2007, 21, 1892-1900.	3.3	102
44	Sleeping Beautyâ€“engineered CAR T cells achieve antileukemic activity without severe toxicities. <i>Journal of Clinical Investigation</i> , 2020, 130, 6021-6033.	3.9	102
45	A single point mutation in the v-ets oncogene affects both erythroid and myelomonocytic cell differentiation. <i>Cell</i> , 1988, 55, 1147-1158.	13.5	99
46	Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. <i>Blood</i> , 1994, 84, 3483-93.	0.6	99
47	The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. <i>Haematologica</i> , 2006, 91, 176-83.	1.7	99
48	Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function.. <i>Journal of Experimental Medicine</i> , 1996, 183, 1841-1850.	4.2	95
49	Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays. <i>Archives of Biochemistry and Biophysics</i> , 2012, 526, 146-153.	1.4	95
50	Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy. <i>Journal of Immunology</i> , 2013, 190, 231-239.	0.4	95
51	Characterization of CD20-Transduced T Lymphocytes as an Alternative Suicide Gene Therapy Approach for the Treatment of Graft-Versus-Host Disease. <i>Human Gene Therapy</i> , 2004, 15, 63-76.	1.4	94
52	The effect of LPS on expression of the early "competence" genes JE and KC in murine peritoneal macrophages. <i>Journal of Immunology</i> , 1987, 138, 3891-6.	0.4	94
53	B-myb antisense oligonucleotides inhibit proliferation of human hematopoietic cell lines. <i>Blood</i> , 1992, 79, 2708-2716.	0.6	90
54	Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. <i>Haematologica</i> , 2003, 88, 1002-12.	1.7	90

#	ARTICLE	IF	CITATIONS
55	Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. <i>Blood</i> , 1996, 87, 1862-72.	0.6	87
56	Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies. <i>Blood</i> , 2017, 129, 2636-2644.	0.6	86
57	INHIBITION OF HUMAN NATURAL KILLER ACTIVITY BY CYCLOSPORIN A. <i>Transplantation</i> , 1981, 31, 113-116.	0.5	82
58	Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2006, 38, 621-627.	1.3	80
59	Transplanted Umbilical Cord Mesenchymal Stem Cells Modify the In Vivo Microenvironment Enhancing Angiogenesis and Leading to Bone Regeneration. <i>Stem Cells and Development</i> , 2015, 24, 1570-1581.	1.1	80
60	Treatment of murine peritoneal macrophages with bacterial lipopolysaccharide alters expression of c-fos and c-myc oncogenes. <i>Journal of Immunology</i> , 1986, 137, 2711-5.	0.4	77
61	Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. <i>Blood</i> , 2003, 101, 4589-4597.	0.6	76
62	Small Dose of Rituximab for Graves Orbitopathy: New Insights Into the Mechanism of Action. <i>JAMA Ophthalmology</i> , 2012, 130, 122.	2.6	75
63	Inducible expression of the long pentraxin PTX3 in the central nervous system. <i>Journal of Neuroimmunology</i> , 2000, 106, 87-94.	1.1	73
64	APO B gene polymorphisms and coronary artery disease: a meta-analysis. <i>Atherosclerosis</i> , 2003, 167, 355-366.	0.4	73
65	Effect of alemtuzumab on neoplastic B cells. <i>Haematologica</i> , 2004, 89, 1476-83.	1.7	72
66	Expression of a long pentraxin, PTX3, by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan. <i>Infection and Immunity</i> , 1997, 65, 1345-1350.	1.0	66
67	Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group. <i>Transplantation</i> , 2009, 88, 614-619.	0.5	64
68	Inhibition of Monocyte Chemotaxis to C-C Chemokines by Antisense Oligonucleotide for Cytosolic Phospholipase A2. <i>Journal of Biological Chemistry</i> , 1996, 271, 6010-6016.	1.6	63
69	Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring. <i>Leukemia</i> , 2012, 26, 1681-1684.	3.3	63
70	Cytokine Activation of Endothelial Cells: New Molecules for an Old Paradigm. <i>Thrombosis and Haemostasis</i> , 1997, 78, 406-414.	1.8	63
71	Intraperitoneal administration of interferon $\hat{2}$ in ovarian cancer patients. <i>Cancer</i> , 1985, 56, 294-301.	2.0	61
72	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2365-2370.	2.0	61

#	ARTICLE	IF	CITATIONS
73	MCP-1 and CCR2 in HIV infection: regulation of agonist and receptor expression. <i>Journal of Leukocyte Biology</i> , 1997, 62, 30-33.	1.5	60
74	Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. <i>Experimental Hematology</i> , 2006, 34, 1218-1228.	0.2	60
75	Natural killer cells in intravenous drug abusers with lymphadenopathy syndrome. <i>Clinical and Experimental Immunology</i> , 1985, 62, 128-35.	1.1	59
76	Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 1359.	2.2	58
77	The myb oncogene family of transcription factors: potent regulators of hematopoietic cell proliferation and differentiation. <i>Seminars in Cancer Biology</i> , 1994, 5, 113-24.	4.3	58
78	Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. <i>Blood</i> , 2011, 117, 510-518.	0.6	57
79	A Human Immunodeficiency Virus Type 1 polGene-Derived Sequence (cPPT/CTS) Increases the Efficiency of Transduction of Human Nondividing Monocytes and T Lymphocytes by Lentiviral Vectors. <i>Human Gene Therapy</i> , 2002, 13, 1793-1807.	1.4	56
80	Nucleolin, a Novel Partner for the Myb Transcription Factor Family That Regulates Their Activity. <i>Journal of Biological Chemistry</i> , 2000, 275, 4152-4158.	1.6	54
81	Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. <i>Leukemia</i> , 2015, 29, 1-10.	3.3	54
82	A-Myb Up-regulates Bcl-2 through a Cdx Binding Site in t(14;18) Lymphoma Cells. <i>Journal of Biological Chemistry</i> , 2000, 275, 6499-6508.	1.6	53
83	Regulation of Inhibitory Pathways of the Interleukin-1 System. <i>Annals of the New York Academy of Sciences</i> , 1998, 840, 338-351.	1.8	52
84	Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33+ acute lymphoblastic leukaemias in vitro and in vivo. <i>British Journal of Haematology</i> , 2005, 128, 310-317.	1.2	52
85	Thrombospondin-1 promotes mesenchymal stromal cell functions via TGF β ² and in cooperation with PDGF. <i>Matrix Biology</i> , 2016, 55, 106-116.	1.5	52
86	CIK as therapeutic agents against tumors. <i>Journal of Autoimmunity</i> , 2017, 85, 32-44.	3.0	52
87	Endothelial Activation by Cytokines. <i>Annals of the New York Academy of Sciences</i> , 1997, 832, 93-116.	1.8	51
88	Regulation of endothelial cell function by pro- and anti-inflammatory cytokines. <i>Transplantation Proceedings</i> , 1998, 30, 4239-4243.	0.3	51
89	Inhibition of natural killer activity by human bronchoalveolar macrophages. <i>Journal of Immunology</i> , 1982, 129, 587-91.	0.4	50
90	Feasibility and Safety of Adoptive Immunotherapy with CIK Cells after Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1603-1607.	2.0	49

#	ARTICLE	IF	CITATIONS
91	Mesenchymal stromal cells for prevention and treatment of graft-versus-host disease. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 72-78.	0.8	48
92	Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2070-2078.	2.0	48
93	Interferon- β inhibits expression of the long pentraxin PTX3 in human monocytes. <i>European Journal of Immunology</i> , 1998, 28, 496-501.	1.6	47
94	The CCL3 Family of Chemokines and Innate Immunity Cooperate In Vivo in the Eradication of an Established Lymphoma Xenograft by Rituximab. <i>Journal of Immunology</i> , 2007, 178, 6616-6623.	0.4	46
95	Human neutrophils express low levels of Fc γ RIIIA, which plays a role in PMN activation. <i>Blood</i> , 2019, 133, 1395-1405.	0.6	46
96	The human A-myb protein is a strong activator of transcription. <i>Oncogene</i> , 1994, 9, 2469-79.	2.6	46
97	Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, slg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias. <i>Blood</i> , 1996, 87, 1900-1911.	0.6	45
98	International Forum on α CD34 ⁺ CD34 ⁺ CD34 ⁺ human platelet lysate for cell propagation: summary. <i>Vox Sanguinis</i> , 2018, 113, 80-87.	0.7	45
99	Innovative Clinical Perspectives for CIK Cells in Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2018, 19, 358.	1.8	44
100	Natural killer cells in human solid tumors. <i>Cancer and Metastasis Reviews</i> , 1983, 2, 337-350.	2.7	42
101	Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death. <i>Blood</i> , 2010, 116, 3372-3373.	0.6	41
102	Clinical grade expansion of MSCs. <i>Immunology Letters</i> , 2015, 168, 222-227.	1.1	41
103	The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable <i>in vitro</i> activity against chronic lymphocytic leukemia B cells with CD20 antibodies. <i>Haematologica</i> , 2017, 102, e400-e403.	1.7	41
104	Intraperitoneal administration of <i>Corynebacterium parvum</i> in patients with ascitic ovarian tumors resistant to chemotherapy: Effects on cytotoxicity of tumor-associated macrophages and NK cells. <i>International Journal of Cancer</i> , 1981, 27, 437-446.	2.3	38
105	B-myb antisense oligonucleotides inhibit proliferation of human hematopoietic cell lines. <i>Blood</i> , 1992, 79, 2708-16.	0.6	38
106	Regulatory domains of the A-Myb transcription factor and its interaction with the CBP/p300 adaptor molecules. <i>Biochemical Journal</i> , 1997, 324, 729-736.	1.7	37
107	Early Activation Signals in Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 423-428.	1.1	37
108	Independent regulation of c-myc, B-myb, and c-myb gene expression by inducers and inhibitors of proliferation in human B lymphocytes. <i>Journal of Immunology</i> , 1992, 149, 300-8.	0.4	37

#	ARTICLE	IF	CITATIONS
109	Molecular evidence of inefficient transduction of proliferating human B lymphocytes by VSV-pseudotyped HIV-1-derived lentivectors. <i>Virology</i> , 2004, 325, 413-424.	1.1	36
110	Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. <i>Haematologica</i> , 2010, 95, 260-269.	1.7	36
111	The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells. <i>Experimental Hematology</i> , 2012, 40, 634-645.e10.	0.2	36
112	Ectopic expression of the erythrocyte band 3 anion exchange protein, using a new avian retrovirus vector. <i>Journal of Virology</i> , 1990, 64, 5891-5902.	1.5	36
113	Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. <i>British Journal of Haematology</i> , 2002, 119, 923-929.	1.2	35
114	Functional transfer of CD40L gene in human B-cell precursor ALL blasts by second-generation SIN lentivectors. <i>Gene Therapy</i> , 2004, 11, 85-93.	2.3	35
115	Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice. <i>PLoS ONE</i> , 2018, 13, e0196048.	1.1	34
116	The A-Myb transcription factor is a marker of centroblasts in vivo. <i>Journal of Immunology</i> , 1998, 160, 2786-93.	0.4	34
117	How can oncogenic transcription factors cause cancer: a critical review of the myb story. <i>Leukemia</i> , 1999, 13, 1301-1306.	3.3	33
118	Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System. <i>Molecular Therapy</i> , 2020, 28, 1974-1986.	3.7	33
119	Defective natural killer activity within human ovarian tumors: low numbers of morphologically defined effectors present in situ. <i>Journal of the National Cancer Institute</i> , 1983, 70, 21-6.	3.0	32
120	The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia. <i>PLoS ONE</i> , 2013, 8, e58424.	1.1	31
121	Direct involvement of CD56 in cytokine-induced killer-mediated lysis of CD56+ hematopoietic target cells. <i>Experimental Hematology</i> , 2014, 42, 1013-1021.e1.	0.2	31
122	Phenotypical and Functional Characteristics of in Vitro-Expanded Adipose-Derived Mesenchymal Stromal Cells from Patients with Systemic Sclerosis. <i>Cell Transplantation</i> , 2017, 26, 841-854.	1.2	31
123	Expression of c-myb and B-myb, but not A-myb, correlates with proliferation in human hematopoietic cells. <i>Blood</i> , 1991, 77, 149-58.	0.6	31
124	Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells. <i>British Journal of Cancer</i> , 1983, 48, 515-525.	2.9	30
125	Characterization of type II intracellular IL-1 receptor antagonist (IL-1ra3): a depot IL-1ra. <i>European Journal of Immunology</i> , 1999, 29, 781-788.	1.6	30
126	The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs. <i>Cytotherapy</i> , 2009, 11, 403-413.	0.3	30

#	ARTICLE	IF	CITATIONS
127	Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms. <i>Immunology Letters</i> , 2013, 155, 27-30.	1.1	30
128	Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2V617F myeloproliferative neoplasm patients. <i>Experimental Hematology</i> , 2013, 41, 253-260.e2.	0.2	30
129	B-myb antisense oligonucleotides inhibit proliferation of human hematopoietic cell lines. <i>Blood</i> , 1992, 79, 2708-2716.	0.6	30
130	Modulation of cell cycle by graded expression of MLL-AF4 fusion oncoprotein. <i>Leukemia</i> , 2004, 18, 1064-1071.	3.3	29
131	Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols. <i>Haematologica</i> , 2014, 99, e94-e97.	1.7	29
132	Multiple intracerebroventricular injections of human umbilical cord mesenchymal stem cells delay motor neurons loss but not disease progression of SOD1G93A mice. <i>Stem Cell Research</i> , 2017, 25, 166-178.	0.3	29
133	Homologous and heterologous desensitization of proto-oncogene c-fos expression in murine peritoneal macrophages. <i>Journal of Cellular Physiology</i> , 1987, 131, 36-42.	2.0	28
134	Mesenchymal Stromal Cells Do Not Increase the Risk of Viral Reactivation Nor the Severity of Viral Events in Recipients of Allogeneic Stem Cell Transplantation. <i>Stem Cells International</i> , 2012, 2012, 1-6.	1.2	28
135	Inhibition of natural killer activity by tumor-associated lymphoid cells from ascites ovarian carcinomas. <i>Journal of the National Cancer Institute</i> , 1981, 67, 319-25.	3.0	28
136	Direct Reprogramming of Human Bone Marrow Stromal Cells into Functional Renal Cells Using Cell-free Extracts. <i>Stem Cell Reports</i> , 2015, 4, 685-698.	2.3	27
137	The early competence genes JE and KC are differentially regulated in murine peritoneal macrophages in response to lipopolysaccharide. <i>Biochemical and Biophysical Research Communications</i> , 1987, 149, 969-974.	1.0	26
138	Regulation of hematopoietic cell proliferation and differentiation by the myb oncogene family of transcription factors. <i>International Journal of Clinical and Laboratory Research</i> , 1996, 26, 24-32.	1.0	26
139	Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. <i>Stem Cell Research and Therapy</i> , 2018, 9, 220.	2.4	26
140	Preventive administration of Mycobacterium tuberculosis 10-kDa heat shock protein (hsp10) suppresses adjuvant arthritis in Lewis rats. <i>International Immunopharmacology</i> , 2002, 2, 463-474.	1.7	25
141	A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy. <i>Journal of Immunology</i> , 2014, 193, 4739-4747.	0.4	24
142	Dissociation between p3B-myb and p75c-myb expression during the proliferation and differentiation of human myeloid cell lines. <i>Blood</i> , 1994, 83, 1778-1790.	0.6	23
143	Endothelial cell regulation of leukocyte infiltration in inflammatory tissues. <i>Mediators of Inflammation</i> , 1995, 4, 322-330.	1.4	23
144	Rapid retroviral infection of human haemopoietic cells of different lineages: efficient transfer in fresh T cells. <i>British Journal of Haematology</i> , 1998, 103, 449-461.	1.2	22

#	ARTICLE	IF	CITATIONS
145	First Report of a Successful Pregnancy in an Everolimus-Treated Heart-Transplanted Patient: Neonatal Disappearance of Immunosuppressive Drugs. <i>American Journal of Transplantation</i> , 2016, 16, 1319-1322.	2.6	22
146	A point mutation in the DNA binding domain of the v-myb oncogene of E26 virus confers temperature sensitivity for transformation of myelomonocytic cells. <i>Oncogene Research</i> , 1988, 3, 313-22.	1.2	22
147	Efficient lentiviral transduction of primary human acute myelogenous and lymphoblastic leukemia cells. <i>Haematologica</i> , 2001, 86, 13-6.	1.7	22
148	Negative regulators of the interleukin-1 system: receptor antagonists and a decoy receptor. <i>International Journal of Clinical and Laboratory Research</i> , 1996, 26, 7-14.	1.0	21
149	The A-myb gene is preferentially expressed in tonsillar CD38+, CD39-, and sIgM- B lymphocytes and in Burkitt's lymphoma cell lines. <i>Journal of Immunology</i> , 1994, 153, 543-53.	0.4	21
150	CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon- γ production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia. <i>Leukemia</i> , 2002, 16, 2046-2054.	3.3	20
151	Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration. <i>Stem Cells Translational Medicine</i> , 2020, 9, 427-432.	1.6	20
152	Third-party bone marrow-derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial. <i>American Journal of Transplantation</i> , 2021, 21, 2795-2809.	2.6	20
153	Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, sIg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias. <i>Blood</i> , 1996, 87, 1900-11.	0.6	20
154	C-myb, but not B-myb, Upregulates Type I Collagen Gene Expression in Human Fibroblasts. <i>Journal of Investigative Dermatology</i> , 1999, 112, 191-196.	0.3	19
155	Longitudinal tracking of triple labeled umbilical cord derived mesenchymal stromal cells in a mouse model of Amyotrophic Lateral Sclerosis. <i>Stem Cell Research</i> , 2015, 15, 243-253.	0.3	19
156	c-myb Proto-Oncogene Is Expressed by Quiescent Scleroderma Fibroblasts and, Unlike B-myb Gene, Does Not Correlate With Proliferation. <i>Journal of Investigative Dermatology</i> , 1996, 106, 1281-1286.	0.3	17
157	Characterization of the c-Myb-responsive Region and Regulation of the Human Type I Collagen $\alpha 2$ Chain Gene by c-Myb. <i>Journal of Biological Chemistry</i> , 2003, 278, 1533-1541.	1.6	17
158	Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 273-286.	2.0	17
159	Large granular lymphocyte/natural killer cell proliferative disease: Clinical and laboratory heterogeneity. <i>Scandinavian Journal of Haematology</i> , 1986, 37, 91-96.	0.0	17
160	Tolerance to Bone Marrow Transplantation: Do Mesenchymal Stromal Cells Still Have a Future for Acute or Chronic GvHD?. <i>Frontiers in Immunology</i> , 2020, 11, 609063.	2.2	17
161	Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells. <i>Journal of the National Cancer Institute</i> , 1982, 68, 555-62.	3.0	17
162	A-myb rescues murine B-cell lymphomas from IgM-receptor-mediated apoptosis through c-myb transcriptional regulation. <i>Blood</i> , 2000, 96, 1013-1020.	0.6	16

#	ARTICLE	IF	CITATIONS
163	Induction of cytotoxicity by interleukin-2 in t ^h 3-lymphoproliferative disorders. <i>International Journal of Cancer</i> , 1986, 37, 27-33.	2.3	15
164	Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: High cytotoxic potential against AML and ALL cells. <i>Experimental Hematology</i> , 2006, 34, 475-485.	0.2	15
165	Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: Best practices and clinical significance. <i>Cytotherapy</i> , 2018, 20, 262-270.	0.3	15
166	Outbreak of persistent, unexplained, generalized lymphadenopathy with immunological abnormalities in drug addicts in Milan. <i>Infection</i> , 1984, 12, 372-376.	2.3	14
167	A simple and rapid method to analyze specific mRNAs from few cells in a semi-quantitative way using the polymerase chain reaction.. <i>Genome Research</i> , 1991, 1, 144-145.	2.4	14
168	Reactive oxygen intermediates cause rapid release of the interleukin-1 decoy receptor from human myelomonocytic cells. <i>Blood</i> , 1996, 87, 1682-1686.	0.6	14
169	The A-Myb Transcription Factor in Neoplastic and Normal B Cells. <i>Leukemia and Lymphoma</i> , 1997, 26, 271-279.	0.6	14
170	Lymphokine Production in Ty Lymphoproliferative Disorders. <i>Scandinavian Journal of Immunology</i> , 1986, 23, 183-188.	1.3	13
171	Migratory Response of Human NK Cells to Monocyte-Chemotactic Proteins. <i>Methods</i> , 1996, 10, 145-149.	1.9	13
172	The DNA Binding Domain of the A-MYB Transcription Factor Is Responsible for Its B Cell-specific Activity and Binds to a B Cell 110-kDa Nuclear Protein. <i>Journal of Biological Chemistry</i> , 1997, 272, 24921-24926.	1.6	13
173	Isolation and characterization of the human A-myb promoter: regulation by NF- κ B and Sp1. <i>Oncogene</i> , 2000, 19, 3931-3940.	2.6	13
174	Detection of a transcriptional block in the first intron of the human c-myb gene. <i>International Journal of Clinical and Laboratory Research</i> , 1992, 22, 159-164.	1.0	12
175	Complement in antibody therapy: friend or foe?. <i>Blood</i> , 2009, 114, 5247-5248.	0.6	12
176	Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models. <i>Experimental Hematology</i> , 2010, 38, 259-269.e2.	0.2	12
177	A policy for the disposal of autologous hematopoietic progenitor cells: report from an Italian consensus panel. <i>Transfusion</i> , 2014, 54, 2353-2360.	0.8	12
178	Identification of Two Novel Isoforms of the ZNF162 Gene: A Growing Family of Signal Transduction and Activator of RNA Proteins. <i>Genomics</i> , 1997, 42, 268-277.	1.3	11
179	International Forum on GMP-grade human platelet lysate for cell propagation. <i>Vox Sanguinis</i> , 2018, 113, e1-e25.	0.7	11
180	Innovative cell-based therapies in onco-hematology: what are the clinical facts ?. <i>Haematologica</i> , 2004, 89, 1253-60.	1.7	9

#	ARTICLE	IF	CITATIONS
181	Interleukin-1 and Tumor Necrosis Factor Induce Transient Expression of an Inhibitor of Nuclear Factor κ B in Endothelial Cells. <i>Endothelium: Journal of Endothelial Cell Research</i> , 1993, 1, 161-165.	1.7	8
182	Chemokines and antagonists in non-Hodgkin's lymphoma. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 621-635.	1.5	8
183	Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumors. <i>Cytotherapy</i> , 2018, 20, 1077-1088.	0.3	8
184	Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories. <i>Cytotherapy</i> , 2016, 18, 481-486.	0.3	7
185	A comprehensive report of long-term stability data for a range ATMPs: A need to develop guidelines for safe and harmonized stability studies. <i>Cytotherapy</i> , 2022, 24, 544-556.	0.3	7
186	Molecular events underlying interleukin-6 independence in a subclone of the CMA-603 multiple myeloma cell line. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 154-167.	1.5	6
187	Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey. <i>Cytotherapy</i> , 2014, 16, 101-110.	0.3	6
188	Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin. <i>Journal of Visualized Experiments</i> , 2019, . .	0.2	6
189	Expression of c-myb and B-myb, but not A-myb, correlates with proliferation in human hematopoietic cells. <i>Blood</i> , 1991, 77, 149-158.	0.6	6
190	Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. <i>Blood</i> , 1994, 84, 3483-3493.	0.6	6
191	Dissociation between p93B-myb and p75c-myb expression during the proliferation and differentiation of human myeloid cell lines. <i>Blood</i> , 1994, 83, 1778-90.	0.6	6
192	Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. <i>Cytokine</i> , 1994, 6, 544.	1.4	5
193	Characterization of migratory activity and cytokine profile of helper and cytotoxic CMV-specific T-cell lines expanded by a selective peptide library. <i>Experimental Hematology</i> , 2008, 36, 473-485.	0.2	5
194	Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation. <i>Blood</i> , 2016, 128, 1160-1160.	0.6	5
195	Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use. <i>Cytotherapy</i> , 2022, 24, 334-343.	0.3	5
196	Evaluation of absorption with Limulus amoebocyte lysate to remove contaminating endotoxin from interferon and lymphokine preparations. <i>Journal of Immunological Methods</i> , 1984, 66, 103-112.	0.6	4
197	Suicide gene therapy and the control of graft-vs-host disease. <i>Best Practice and Research in Clinical Haematology</i> , 2004, 17, 453-463.	0.7	3
198	NATURAL KILLER ACTIVITY IN HUMAN OVARIAN TUMORS. , 1982, , 1119-1126.		3

#	ARTICLE	IF	CITATIONS
199	Understanding the Immunomodulatory Effect of Mesenchymal Stem Cell Infused In Transplanted Patients with Steroid-Refractory GvHD. <i>Blood</i> , 2010, 116, 2306-2306.	0.6	3
200	A Multicenter Phase II Study of Sequential Administration of Unmanipulated DLI and Donor Derived Cytokine Induced Killer (CIK) Cells in HSCT Patients, Relapsed of Disease. <i>Blood</i> , 2015, 126, 3160-3160.	0.6	3
201	Dissociation between p93B-myb and p75c-myb expression during the proliferation and differentiation of human myeloid cell lines. <i>Blood</i> , 1994, 83, 1778-1790.	0.6	3
202	Cytokine Regulation of Endothelial Cell Function. , 1998, , 105-134.		2
203	The Role of Oncogenes in Myeloid Differentiation. , 1992, , 504-518.		2
204	A Phase II Study of Sequential Administration of DLI and Cytokine Induced Killer (CIK) Cells in Patients with Hematologic Malignancies Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation: Preliminary Results. <i>Blood</i> , 2011, 118, 657-657.	0.6	2
205	A-myb rescues murine B-cell lymphomas from IgM-receptor-mediated apoptosis through c-myctranscriptional regulation. <i>Blood</i> , 2000, 96, 1013-1020.	0.6	2
206	Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase I Study On 47 Adult and Pediatric Patients. <i>Blood</i> , 2012, 120, 743-743.	0.6	2
207	Immunomonitoring of Transplanted Patients Infused With Mesenchymal Stromal Cells (MSC) for Treating Steroid-Refractory GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S162-S163.	2.0	1
208	Disposal of the residual autologous HSC units: Results of a survey carried out two years after the publication of a national policy in Italy. <i>Transfusion and Apheresis Science</i> , 2018, 57, 197-200.	0.5	1
209	Protective Effects of Human Nonrenal and Renal Stromal Cells and Their Conditioned Media in a Rat Model of Chronic Kidney Disease. <i>Cell Transplantation</i> , 2020, 29, 096368972096546.	1.2	1
210	Human Umbilical Cord Derived Mesenchymal Stromal Cells to Treat Steroid-Refractory Acute GvHD III/IV or Overlap Syndrome: Interim Analysis of a Multicenter Phase I/II Study. <i>Blood</i> , 2018, 132, 3404-3404.	0.6	1
211	Infusion of Donor Derived Cytokine Induced Killer Cells May Induce Clinical Remission with Limited GVHD in Patients Relapsing after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 3698-3698.	0.6	1
212	Massive, Clinical Grade Expansion Of Polyclonal T Cells Using Blinatumomab For Adoptive Autologous Cellular Therapy Of CLL Patients. <i>Blood</i> , 2013, 122, 3272-3272.	0.6	1
213	Human Macrophages Phagocytose Rituximab Opsonised Leukemic Cells Via CD16, CD32 and CD64 but Do Not Mediate ADCC.. <i>Blood</i> , 2006, 108, 2507-2507.	0.6	1
214	Human Mesenchymal Stroma Cells (hMSCs) Expanded with Human Platelets Lysate Are Safe and Effective For the Treatment of Graft Versus Host Disease. <i>Blood</i> , 2008, 112, 1171-1171.	0.6	1
215	Impairment of human NK activity by cyclosporin A. <i>International Journal of Immunopharmacology</i> , 1980, 2, 219.	1.1	0
216	Effect of i.p. C. Parvum on the tumoricidal activity of tumor-associated macrophages and tumor-associated lymphocytes from ascitic ovarian tumors. <i>International Journal of Immunopharmacology</i> , 1982, 4, 261.	1.1	0

#	ARTICLE	IF	CITATIONS
217	The Regulatory Situation for Academic Cell Therapy Facilities in Europe. , 2009, , 27-35.		0
218	Platelet-Lysate-Expanded Mesenchymal Stromal Cells for the Treatment of Resistant GVHD. Biology of Blood and Marrow Transplantation, 2011, 17, S169.	2.0	0
219	Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Mesenchymal Stromal Cells: A Prospective, Multicentric, Phase 1 Study. Biology of Blood and Marrow Transplantation, 2013, 19, S135.	2.0	0
220	Potent Inhibition of EEC Colony Formation in JAK2V617F PV and ET by Low Doses of ITF2357, a New Histone Deacetylase Inhibitor.. Blood, 2006, 108, 2702-2702.	0.6	0
221	Cytotoxicity on Tumor Cells of Human Macrophages: Functional Status of Tumor-Associated Effector Cells. Advances in Experimental Medicine and Biology, 1982, 141, 99-108.	0.8	0
222	Cytokine Activation of Endothelium: Cloning and Characterization of a New IL-1 Inducible Gene. , 1996, , 139-144.		0
223	Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation. Blood, 2016, 128, 3374-3374.	0.6	0
224	Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications. Blood, 2018, 132, 196-196.	0.6	0